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Abstract
A novel approach to multiclass tumor classification using Artificial Neural Networks
(ANNs) was introduced in a recent paper [1]. The method successfully classified and diag-
nosed small, round blue cell tumors (SRBCTs) of childhood into four distinct categories,
neuroblastoma (NB), rhabdomyosarcoma (RMS), non-Hodgkin lymphoma (NHL) and the
Ewing family of tumors (EWS), using cDNA gene expression profiles of samples that in-
cluded both tumor biopsy material and cell lines. We report that using an approach similar
to the one reported by Yeang et al [2], i.e. multiclass classification by combining outputs
of binary classifiers, we achieved equal accuracy with much fewer features. We report the
performances of 3 binary classifiers (k-nearest neighbors (kNN), weighted-voting (WV), and
support vector machines (SVM)) with 3 feature selection techniques (Golub's Signal to Noise
(SN) ratios [3], Fisher scores (FSc) and Mukherjee's SVM feature selection (SVMFS))[4].
1 Introduction
There currently exists no single biological or chemical test that can precisely distinguish small,
round blue cell tumors of childhood (SRBCTs) into their subclasses, which include neuroblas-
toma (NB), rhabdomyosarcoma (RMS), non-Hodgkin lymphoma (NHL) and the Ewing family
of tumors (EWS) [1]. A recent paper by Khan et al. reports that using gene expression proles
obtained from cDNA microarrays of samples which included both tumor tissue as well as cell
lines, articial neural networks (ANNs) can accurately distinguish the tumor sub-types using 96
top genes obtained from Principal Component Analysis from the more than 6000 genes of which
the expression was measured. In order to identify candidate targets for therapy, it is of course
important to identify a small subset of genes and yet retain high classication accuracy. Using
an approach similar to that of Yeang et al [2], we have performed multiclass classication using 3
binary classiers (k-nearest neighbors (kNN), weighted-voting (WV), and linear support vector
machines (SVM)) in a one-versus-rest fashion with 3 feature selection techniques (Golub's Signal
to Noise (SN) ratios [3], Fisher scores (FSc) and Mukherjee's SVM feature selection (SVMFS))[4].
With all of these techniques we have obtained accuracy equal to Khan et al. with much fewer
genes (features).
2 Dataset
Khan et al. ltered the 6567 cDNA gene expression proles by requiring a minimal intensity of
expression, which reduced the number of genes to 2308. Khan et al. then generated 3750 (lin-
ear!) ANN models by minimizing the summed squared error using three-fold cross-validation.
The genes were ranked by their signicance for the classication using the 3750 previously cal-
ibrated models. Using the top 96 genes, Khan et al. achieved 0 error on their training data
set of 63 samples. A set of 25 test samples, which included 6 EWS, 3 BL,6 NB,5 RMS and
5 non-SRBCTs (consisting of 2 normal muscle tissues and 3 cell lines including an undieren-
tiated sarcoma, osteosarcoma and a prostate carcinoma) were correctly classied (the 5 non-
SRBCTs were excluded by a 95% percentile distance) by the ANNs. We downloaded the data
set (http://www.nhgri.nih.gov/DIR/Microarray/Supplement/) consisting of 64 training samples
(23 EWS; 8 Burkitt lympohmas (BL), a subset of NHL; 12 NB and 21 RMS samples) that be-
longed to a total of 4 classes and 25 test samples (6 EWS, 3 BL,6 NB,5 RMS and 5 non-SRBCTs
(consisting of 2 normal muscle tissues and 3 cell lines including an undierentiated sarcoma,
osteosarcoma and a prostate carcinoma). Each sample was a feature vector of 2308 natural log-
normalized gene expression values.
3 One-versus-rest Multiclass
In solving multiclass problems using binary classiers combined in a one-versus-rest fashion, each
classier trained on one class versus the rest of the classes makes a prediction about a given test
sample. A sample's predicted label is the class for which that classier returned a positive label,
and for which the rest of the classiers returned negative labels. Sample predictions can be
rejected in these two cases: (1) If each of the 4 binary classiers does not predict that the sample
1
is in its respective classes. (2) If conicting predictions arise i.e. 2 or more binary classiers
predict that the sample belongs in their respective classes. Results with rejection are indicated
in the tables below by \w.r.".
In the tables below, (signed) refers to using the signed SVM labels to determine the class predic-
tion (hard errors [2]), and (max) refers to assigning the class label for which the distance from
the margin in the positive direction (i.e. the direction in which that class resides rather than the
\rest") is maximal. This approach has been used to solve other multiclass pattern recognition
problems [7]. We can also determine the condence of the prediction using the magnitudes of
the SVM outputs. Figure 1 shows examples of rejections and low condence samples.
4 Feature Selection
Features were selected by three methods, namely, Golub's Signal to Noise (S2N) ratios [3], Fisher
scores (FSc), which is similar to S2N ratios and Murkerjee et al's SVM feature selection tech-
nique (SVMFS))[4]. Binary classiers (WV, SVM and kNN) were combined in a one-versus-rest
fashion to perform multiclass classication. We performed leave-one-out cross validation on the
training data set, using top genes ranked by the various feature selection methods. In the tables
below, the top X genes means X genes discriminated one class from the rest of the classes, and
because there are four classes, the total number of genes used are 4 times X, or fewer, as there
are overlaps in some of the gene subsets. For example, 5 S2N genes (in the table below) means
using top 5 genes from Table 8, top 5 genes from Table 9, top 5 genes from Table 10 and top
5 genes from Table 11. The results for the 20 SRBCT test samples are presented below. The
bracketed numbers are the Leave-One-Out Cross Validation (LOOCV) error for the 64 training
samples.
As a reminder, Golub et al's Signal to Noise Ratio (S2N) used to rank genes (features) corresponds
to the following statistic:
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A related coeÆcient has been used in Pavlidis et al. [6], which we term Fisher scores (FSc) as
it's similar to Fisher's discriminant criterion [5]:
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Mukherjee et al. formulated a more direct SVM feature selection algorithm. During the QP
minimization the input space is rescaled such that the margin in feature space increases subject
to the constraint that the volume feature space remains constant[4]. In particular, a diagonal
matrix A of scaling factors a
1
; a
2
:::a
n
is incorporated into the kernel:
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KA
(x;y) = K(Ax; Ay) (3)
and training is performed by the following iterative steps: 1) Optimize the 's for a xed A and
2) Optimize A for xed 's by gradient descent. The genes with the largest scaling factors are
selected as important features.
5 Classication Results
Referring to Table 1, SVM (max) achieves perfect performance (on the 20 SRBCT test samples)
and made 1 LOOCV error using all 2308 genes (Figure 1), compared to 2 test errors and 4
LOOCV errors made by kNN and 9 test errors and 19 LOOCV error made by WV. The sample
misclassied during LOOCV by SVM (max) is EWS-T13 [1]. This sample occurs frequently as
a LOOCV error, which agrees with Khan et al's analysis, who opined that EWS-T13 cannot
be condently diagnosed (as it fell outside the expected 95th percentile distance of a perfect
vote). The sample that is misclassied by SVM (signed) is RMS-T9 which occurs the next most
frequently. Khan et al's analysis reported training with 63 samples, and excluded this sample [1].
kNN kNN w.r. WV WV w.r. SVM (signed) SVM (signed) w.r. SVM (max)
2 (4) 2 (4) 9 (19) 4 (4) 0 (2) 0 (1) 0 (1)
Table 1: Test errors (20 samples) using all genes. LOOCV errors (64 samples) in brackets. (signed)
refers to signed output as predicted class, (max) refers to maximal output as predicted class. w.r. stands
for \with rejections".
FSc kNN kNN w.r. WV WV w.r. SVM (signed) SVM (signed) w.r. SVM (max)
100 0 (2) 0 (1) 3 (2) 0 (0) 0 (2) 0 (0) 0 (0)
60 2 (3) 0 (0) 4 (2) 0 (0) 1 (2) 0 (0) 0 (0)
20 2 (3) 1 (0) 2 (2) 1 (0) 2 (3) 1 (0) 1 (0)
10 3 (2) 1 (0) 1 (2) 1 (0) 4 (3) 1 (0) 1 (0)
5 4 (2) 0 (0) 6 (4) 0 (0) 4 (4) 0 (0) 1 (0)
S2N kNN kNN w.r. WV WV w.r. SVM (signed) SVM (signed) w.r. SVM (max)
100 0 (2) 0 (1) 2 (0) 0(0) 0 (2) 0 (0) 0 (0)
60 0 (2) 0 (0) 1 (0) 0(0) 1 (3) 0 (0) 0 (0)
20 2 (2) 0 (0) 1 (1) 0(0) 3 (2) 0 (0) 1 (0)
10 1 (2) 1 (0) 1 (2) 1(0) 2 (3) 1 (0) 1 (0)
5 2 (2) 1 (0) 2 (4) 0(0) 2 (2) 0 (0) 0 (0)
SVMFS kNN kNN w.r. WV WV w.r. SVM (signed) SVM (signed) w.r. SVM (max)
100 1 (1) 0 (1) 0 (0) 0 (0) 0 (1) 0 (0) 0 (0)
60 0 (0) 0 (0) 1 (0) 0 (0) 0 (1) 0 (0) 0 (0)
20 2 (2) 1 (0) 2 (1) 1 (0) 1 (0) 1 (0) 1 (0)
10 3 (3) 1 (1) 4 (2) 1 (0) 1 (2) 1 (0) 1 (0)
5 6 (5) 1 (0) 7 (6) 1 (0) 7 (4) 1 (0) 1 (1)
Table 2: Test errors (20 samples). LOOCV errors (64 samples) in brackets. (signed) refers to signed
output as predicted class, (max) refers to maximal output as predicted class. w.r. stands for \with
rejections". Left column is top number of genes ranked by FSc, S2N or SVMFS used to train one
classier (multiply by 4 to get max possible number of distinct genes).
Table 2 presents the errors for the 20 SRBCT test samples and the LOOCV errors for the 64
training samples in brackets, achieved by the dierent classication methods, for dierent feature
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selection methods, and number of features used. The numbers in bold are the best errors in
each row for the errors achieved without rejections of samples (as described above). It is evident
that SVM (max) achieves better results. Rejection of samples reduces the errors, in most cases,
to 1 or even 0. Also, using SVMFS reduces errors for kNN, WV and SVM (signed) when using
larger numbers of features (20, 60, 100 per class). However, SVMS performed poorly for smaller
sets of genes (5,10). SVMFS distributes the importance of features to get better classication
accuracy but by using more features.
Table 3 presents the predicted classes of the 5 non-SRBCT samples in the test set, retaining
the sample names as used in the Khan et al's paper [1]. A value of \0" in the table means the
non-SRBCT test sample was rejected (by the conditions above). Test 9 and 13 are 2 normal
muscle tissues and the rest were from cell lines: an undierentiated sarcoma (Test 5), osteosar-
coma (Test 3) and prostate carcinoma (Test 11). Test 9, 11, 5, 13 and 3 were predicted by Khan
et al's ANNs to be classes 4, 1, 3, 4 and 4 respectively (1,2,3,4 referring to EWS, BL, NB and
RMS). The best performance with regard to the non-SRBCTs was achieved by SVM with the
top 5 genes per class (20 in total) selected by SVMFS, which predicted that all 5 non-SRBCT
samples did not belong in any of the 4 classes. Using top 5 genes per class (20 in total) selected
by S2N or FSc resulted in 1 mistake out of the 5 non-SRBCT samples made by SVM, Test 13
(predicted to be class 4), which agrees with the ANN prediction [1]. The one test sample that is
misclassied by almost all methods is Test 20, which agrees with Khan et al's [1] analysis. Fig-
ure 2 depicts the typical low condences associated with both Test 13 and Test 20. In addition,
it may be biologically signicant that Test 9 and 13 (skeletal muscle tissues) are misclassied
often as belonging to subclass EWS.
Genes Sample FSc-kNN FSc-WV FSc-SVM S2N-kNN S2N-WV S2N-SVM SVMFS-kNN SVMFS-WV SVMFS-SVM
100 Test 9 4 4 4 4 4 4 4 4 4
100 Test 11 0 0 0 0 0 0 0 0 0
100 Test 5 0 0 0 0 0 0 0 0 0
100 Test 13 4 4 4 4 4 4 4 4 4
100 Test 3 0 0 0 4 0 0 0 0 0
60 Test 9 0 4 4 0 4 0 4 4 4
60 Test 11 0 0 0 0 0 0 0 0 0
60 Test 5 0 0 0 0 0 0 1 0 0
60 Test 13 4 4 4 4 4 4 4 4 4
60 Test 3 1 0 0 1 0 0 0 0 0
20 Test 9 0 0 0 0 0 0 4 0 4
20 Test 11 0 0 0 0 0 0 0 0 0
20 Test 5 0 0 0 0 0 0 0 0 0
20 Test 13 0 0 0 0 0 0 4 4 4
20 Test 3 0 0 0 0 0 0 0 0 0
10 Test 9 0 0 0 0 0 0 0 4 4
10 Test 11 0 0 0 0 0 0 0 0 0
10 Test 5 0 0 0 0 0 0 0 0 0
10 Test 13 0 4 0 0 4 4 4 0 0
10 Test 3 0 0 0 0 0 0 0 0 0
5 Test 9 0 0 0 0 0 0 4 4 0
5 Test 11 0 0 0 0 0 0 0 0 0
5 Test 5 0 0 0 0 0 0 0 0 0
5 Test 13 4 4 4 4 4 4 0 0 0
5 Test 3 0 0 0 0 0 0 1 0 0
Table 3: Predicted labels for 5 non-SRBCT Test samples. (1,2,3,4 refers to predicted as EWS, BL, NB
and RMS, 0 refers to rejection).
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In summary, SVM(max) is able to achieve 0 test error and 0 LOOCV error, but made 1 mistake
(with rejections) in the non-SRBCTs, using a total of 20 genes (5 genes per class) ranked by
S2N (refer to Figure 3). Since the genes involved may be biologically relevant, then we suggest
that these 20 genes should be investigated biologically. The list of genes ranked by the dierent
feature selection schemes are in the appendix.
6 Comparing Ranking of Genes
Table 16 and Table 17 compare the top 10 genes (per class) ranked by S2N and SVMFS (FSc
gives similar features to S2N) with the rank of the genes in Khan et al's analysis [1]. 22 of the
40 genes ranked by S2N and 20 of the 40 genes ranked by SVMFS overlap with Khan et al's top
96 genes.
7 Conclusion
Small round, blue cell tumors can be easily classied into their classes by classical methods for
classication, such as Weighted voting, kNN, and linear SVM classiers (a special case extension
of classical regularization approach). Khan et al. used a one-layer ANN, which is in eect a
very simple linear discriminant method (not regularized and thus just minimizing the empirical
error), motivating us to use other classical methods better suited for classication to assess
accuracy and gene selection. The methods used in this paper are generally comparable in terms
of performance, regardless of the feature selection algorithm ( Signal to Noise, Fisher scores and
SVM feature selection (SVMFS). SVMFS improves accuracy for dierent classication methods
when relatively large numbers of features are used, but fails when very small numbers are used. It
may be best to consider the genes selected by SVMFS to discriminate samples when large feature
spaces are available, and the genes selected by, say, S2N when it is of pharmaceutical interest
to pick few genes. Using the maximal SVM outputs gives the best accuracy (1 low condence
error for Test 13 (non-SRBCT)) with just 20 genes (in total) ranked by their Signal to Noise
ratios. Rejection of samples in this multiclass scheme is useful for reducing errors, and may
indicate biological peculiarities in the rejected samples. Lastly, the top genes (in appendix) are
candidates for further histochemical and biological validation. Notice that it cannot be expected
in general that successful classication of tumor types may be achieved using a small number
of genes (P. Tamayo, personal communication). When, however, this is possible as in the case
discussed here, it is likely to be biologically signicant.
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Figure 1: (a) The rst sample (from the left) has high condence, the second and third are low
condence and also rejectable, and the fourth is a low condence (non-rejectable) sample. The
four bars (per sample) are the outputs of the 4 linear SVMs. (b) SVM LOOCV outputs using
all genes (64 samples).
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SVM outputs of 5 non−SRBCTs and Test 20 (far right) using 10 (x 4 classes) genes ranked by S2N
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Figure 2: (a) SVM outputs of 5 non-SRBCTs (9,11,5,13,3 from left) and Test 20 (far right) using
10 (x 4 classes) genes ranked by S2N. Note the typical low condences of Test 13 and Test 20.
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SVM outputs (25 test samples) using 5 (x 4 classes) genes ranked by S2N
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Figure 3: (a) SVM outputs (S2N selected top 5 (x 4 classes) genes for all 25 test samples. (b)
5 non-SRBCTs (Test 9, 11, 5, 13, 3 from left to right) from (a). All rejectable except Test 13
(misclassifed as RMS).
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A Ranked Genes by SVMFS
rank Image Id. Gene Description
1 139957 ESTs
2 754649 chromosome 14 open reading frame 3
3 302933 nucleolin
4 897690 tumor rejection antigen (gp96) 1
5 50887 ESTs
6 296448 insulin-like growth factor 2 (somatomedin A)
7 866702 "protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase)"
8 244618 ESTs
9 379708
10 811000 "lectin, galactoside-binding, soluble, 3 binding protein (galectin 6 binding protein)"
11 755578 "solute carrier family 7 (cationic amino acid transporter, y+ system), member 5"
12 194384 basic transcription factor 3
13 627939 cysteine and glycine-rich protein 3 (cardiac LIM protein)
14 1435862 "antigen identied by monoclonal antibodies 12E7, F21 and O13"
15 814260 follicular lymphoma variant translocation 1
16 842861 heterogeneous nuclear ribonucleoprotein R
17 34357 "actin, beta"
18 172751 "amyloid beta (A4) precursor protein-binding, family A, member 1 (X11)"
19 42076 TRK-fused gene (NOTE: non-standard symbol and name)
20 781097 "neurotrophic tyrosine kinase, receptor-related 1"
Table 4: Discriminated Class 1 (EWS) from the rest
rank Image Id. Gene Description
1 868304 "actin, alpha 2, smooth muscle, aorta"
2 840942 "major histocompatibility complex, class II, DP beta 1"
3 233721 insulin-like growth factor binding protein 2 (36kD)
4 745343 "regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein)"
5 47475 "Homo sapiens inducible protein mRNA, complete cds"
6 80109 "major histocompatibility complex, class II, DQ alpha 1"
7 1461138 "H4 histone family, member G"
8 241412 E74-like factor 1 (ets domain transcription factor)
9 344134 immunoglobulin lambda-like polypeptide 3
10 1416782 "creatine kinase, brain"
11 207274 Human DNA for insulin-like growth factor II (IGF-2); exon 7 and additional ORF
12 841620 dihydropyrimidinase-like 2
13 755145 villin 2 (ezrin)
14 626502 "actin related protein 2/3 complex, subunit 1B (41 kD)"
15 208718 annexin A1
16 1493527 asparagine synthetase
17 45544 transgelin 2
18 183337 "major histocompatibility complex, class II, DM alpha"
19 814526 ESTs
20 486110 prolin 2
Table 5: Discriminated Class 2 (BL) from the rest
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rank Image Id. Gene Description
1 629896 microtubule-associated protein 1B
2 812105 transmembrane protein
3 878652 postmeiotic segregation increased 2-like 12
4 810057 cold shock domain protein A
5 44563 growth associated protein 43
6 82225 secreted frizzled-related protein 1
7 784224 broblast growth factor receptor 4
8 135688 GATA-binding protein 2
9 325182 "cadherin 2, N-cadherin (neuronal)"
10 365826 growth arrest-specic 1
11 34355 "calmodulin 2 (phosphorylase kinase, delta)"
12 377461 "caveolin 1, caveolae protein, 22kD"
13 1474174 "matrix metalloproteinase 2 (gelatinase A, 72kD gelatinase, 72kD type IV collagenase)"
14 755239 methyltransferase-like 1
15 950574 "H3 histone, family 3B (H3.3B)"
16 1435862 "antigen identied by monoclonal antibodies 12E7, F21 and O13"
17 244637 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 45620
18 841620 dihydropyrimidinase-like 2
19 812965 v-myc avian myelocytomatosis viral oncogene homolog
20 45544 transgelin 2
Table 6: Discriminated Class 3 (NB) from the rest
rank Image Id. Gene Description
1 207274 Human DNA for insulin-like growth factor II (IGF-2); exon 7 and additional ORF
2 784224 broblast growth factor receptor 4
3 296448 insulin-like growth factor 2 (somatomedin A)
4 840708 "superoxide dismutase 2, mitochondrial"
5 882522 argininosuccinate synthetase
6 302933 nucleolin
7 244618 ESTs
8 878798 beta-2-microglobulin
9 810512 thrombospondin 1
10 52076 olfactomedinrelated ER localized protein
11 629896 microtubule-associated protein 1B
12 45544 transgelin 2
13 377461 "caveolin 1, caveolae protein, 22kD"
14 413633
15 878652 postmeiotic segregation increased 2-like 12
16 33826 mitogen-activated protein kinase kinase 1
17 814260 follicular lymphoma variant translocation 1
18 788107 amphiphysin-like
19 839552 nuclear receptor coactivator 1
20 809603 "ESTs, Weakly similar to cDNA EST EMBL:M89154 comes from this gene [C.elegans]"
Table 7: Discriminated Class 4 (RMS) from the rest
10
B Ranked Genes by S2N
rank Image Id. Gene Description
1 770394 "Fc fragment of IgG, receptor, transporter, alpha"
2 377461 "caveolin 1, caveolae protein, 22kD"
3 814260 follicular lymphoma variant translocation 1
4 1435862 "antigen identied by monoclonal antibodies 12E7, F21 and O13"
5 295985 ESTs
6 866702 "protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase)"
7 491565 "Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2"
8 1471841 "ATPase, Na+/K+ transporting, alpha 1 polypeptide"
9 52076 olfactomedinrelated ER localized protein
10 841641 cyclin D1 (PRAD1: parathyroid adenomatosis 1)
11 43733 glycogenin 2
12 214572 ESTs
13 713922 glutathione S-transferase M1
14 308497 KIAA0467 protein
15 1470048 "lymphocyte antigen 6 complex, locus E"
16 139957 ESTs
17 1473131 "transducin-like enhancer of split 2, homolog of Drosophila E(sp1)"
18 770868 NGFI-A binding protein 2 (ERG1 binding protein 2)
19 357031 "tumor necrosis factor, alpha-induced protein 6"
20 842820 inducible poly(A)-binding protein
Table 8: Discriminated Class 1 (EWS) from the rest
rank Image Id. Gene Description
1 236282 Wiskott-Aldrich syndrome (ecezema-thrombocytopenia)
2 745019 EH domain containing 1
3 183337 "major histocompatibility complex, class II, DM alpha"
4 504791 glutathione S-transferase A4
5 814526 ESTs
6 21652 "catenin (cadherin-associated protein), alpha 1 (102kD)"
7 624360 "proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7)"
8 47475 "Homo sapiens inducible protein mRNA, complete cds"
9 813742 PTK7 protein tyrosine kinase 7
10 897788 "protein tyrosine phosphatase, receptor type, F"
11 897164 "catenin (cadherin-associated protein), alpha 1 (102kD)"
12 1416782 "creatine kinase, brain"
13 490772 small nuclear ribonucleoprotein polypeptide A'
14 1469292 pim-2 oncogene
15 344134 immunoglobulin lambda-like polypeptide 3
16 785793 "capping protein (actin lament) muscle Z-line, alpha 1"
17 241412 E74-like factor 1 (ets domain transcription factor)
18 68977 "proteasome (prosome, macropain) subunit, beta type, 10"
19 204545 ESTs
20 868304 "actin, alpha 2, smooth muscle, aorta"
Table 9: Discriminated Class 2 (BL) from the rest
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rank Image Id. Gene Description
1 812105 transmembrane protein
2 786084 chromobox homolog 1 (Drosophila HP1 beta)
3 134748 glycine cleavage system protein H (aminomethyl carrier)
4 325182 "cadherin 2, N-cadherin (neuronal)"
5 486110 prolin 2
6 629896 microtubule-associated protein 1B
7 810057 cold shock domain protein A
8 81518 apelin; peptide ligand for APJ receptor
9 756401 Ras homolog enriched in brain 2
10 244637 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 45620
11 383188 recoverin
12 810864 "ESTs, Highly similar to CGI-48 protein [H.sapiens]"
13 544664 matrin 3
14 789376 thioredoxin reductase 1
15 308231 "Homo sapiens incomplete cDNA for a mutated allele of a myosin class I, myh-1c"
16 823886 "Smooth muscle myosin heavy chain isoform SMemb [human, umbilical cord, fetal aorta, mRNA Partial, 971 nt]"
17 823775 "guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3"
18 377048 "Homo sapiens incomplete cDNA for a mutated allele of a myosin class I, myh-1c"
19 878652 postmeiotic segregation increased 2-like 12
20 220096
Table 10: Discriminated Class 3 (NB) from the rest
rank Image Id. Gene Description
1 784224 broblast growth factor receptor 4
2 796258 "sarcoglycan, alpha (50kD dystrophin-associated glycoprotein)"
3 244618 ESTs
4 769716 neurobromin 2 (bilateral acoustic neuroma)
5 789253 presenilin 2 (Alzheimer disease 4)
6 839552 nuclear receptor coactivator 1
7 143306 lymphocyte-specic protein 1
8 207274 Human DNA for insulin-like growth factor II (IGF-2); exon 7 and additional ORF
9 296448 insulin-like growth factor 2 (somatomedin A)
10 142134 ESTs
11 898219 mesoderm specic transcript (mouse) homolog
12 25725 farnesyl-diphosphate farnesyltransferase 1
13 813841 "plasminogen activator, tissue"
14 298062 "troponin T2, cardiac"
15 42558 glycine amidinotransferase (L-arginine:glycine amidinotransferase)
16 79022 FBJ murine osteosarcoma viral oncogene homolog B
17 246035 ESTs
18 859359 quinone oxidoreductase homolog
19 814444 "cofactor required for Sp1 transcriptional activation, subunit 9 (33kD)"
20 128054 ESTs
Table 11: Discriminated Class 4 (RMS) from the rest
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C Ranked Genes by FSc
rank Image Id. Gene Description
1 770394 "Fc fragment of IgG, receptor, transporter, alpha"
2 1435862 "antigen identied by monoclonal antibodies 12E7, F21 and O13"
3 377461 "caveolin 1, caveolae protein, 22kD"
4 814260 follicular lymphoma variant translocation 1
5 491565 "Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2"
6 295985 ESTs
7 866702 "protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase)"
8 1471841 "ATPase, Na+/K+ transporting, alpha 1 polypeptide"
9 841641 cyclin D1 (PRAD1: parathyroid adenomatosis 1)
10 713922 glutathione S-transferase M1
11 308497 KIAA0467 protein
12 52076 olfactomedinrelated ER localized protein
13 770868 NGFI-A binding protein 2 (ERG1 binding protein 2)
14 139957 ESTs
15 1470048 "lymphocyte antigen 6 complex, locus E"
16 842820 inducible poly(A)-binding protein
17 1473131 "transducin-like enhancer of split 2, homolog of Drosophila E(sp1)"
18 214572 ESTs
19 1323448 cysteine-rich protein 1 (intestinal)
20 345232 "lymphotoxin alpha (TNF superfamily, member 1)"
Table 12: Discriminated Class 1 (EWS) from the rest
rank Image Id. Gene Description
1 236282 Wiskott-Aldrich syndrome (ecezema-thrombocytopenia)
2 745019 EH domain containing 1
3 814526 ESTs
4 183337 "major histocompatibility complex, class II, DM alpha"
5 624360 "proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7)"
6 47475 "Homo sapiens inducible protein mRNA, complete cds"
7 490772 small nuclear ribonucleoprotein polypeptide A'
8 785793 "capping protein (actin lament) muscle Z-line, alpha 1"
9 344134 immunoglobulin lambda-like polypeptide 3
10 868304 "actin, alpha 2, smooth muscle, aorta"
11 701751 cut (Drosophila)-like 1 (CCAAT displacement protein)
12 840942 "major histocompatibility complex, class II, DP beta 1"
13 21652 "catenin (cadherin-associated protein), alpha 1 (102kD)"
14 813742 PTK7 protein tyrosine kinase 7
15 68977 "proteasome (prosome, macropain) subunit, beta type, 10"
16 504791 glutathione S-transferase A4
17 897164 "catenin (cadherin-associated protein), alpha 1 (102kD)"
18 1469292 pim-2 oncogene
19 297392 metallothionein 1L
20 855487 N-acylsphingosine amidohydrolase (acid ceramidase)
Table 13: Discriminated Class 2 (BL) from the rest
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rank Image Id. Gene Description
1 812105 transmembrane protein
2 786084 chromobox homolog 1 (Drosophila HP1 beta)
3 134748 glycine cleavage system protein H (aminomethyl carrier)
4 486110 prolin 2
5 81518 apelin; peptide ligand for APJ receptor
6 629896 microtubule-associated protein 1B
7 756401 Ras homolog enriched in brain 2
8 244637 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 45620
9 810057 cold shock domain protein A
10 325182 "cadherin 2, N-cadherin (neuronal)"
11 383188 recoverin
12 810864 "ESTs, Highly similar to CGI-48 protein [H.sapiens]"
13 544664 matrin 3
14 789376 thioredoxin reductase 1
15 823775 "guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3"
16 823886 "Smooth muscle myosin heavy chain isoform SMemb [human, umbilical cord, fetal aorta, mRNA Partial, 971 nt]"
17 878652 postmeiotic segregation increased 2-like 12
18 377048 "Homo sapiens incomplete cDNA for a mutated allele of a myosin class I, myh-1c"
19 308231 "Homo sapiens incomplete cDNA for a mutated allele of a myosin class I, myh-1c"
20 811161 ATP-binding cassette 50 (TNF-alpha stimulated)
Table 14: Discriminated Class 3 (NB) from the rest
rank Image Id. Gene Description
1 784224 broblast growth factor receptor 4
2 796258 "sarcoglycan, alpha (50kD dystrophin-associated glycoprotein)"
3 142134 ESTs
4 143306 lymphocyte-specic protein 1
5 769716 neurobromin 2 (bilateral acoustic neuroma)
6 789253 presenilin 2 (Alzheimer disease 4)
7 296448 insulin-like growth factor 2 (somatomedin A)
8 207274 Human DNA for insulin-like growth factor II (IGF-2); exon 7 and additional ORF
9 839552 nuclear receptor coactivator 1
10 244618 ESTs
11 79022 FBJ murine osteosarcoma viral oncogene homolog B
12 813841 "plasminogen activator, tissue"
13 898219 mesoderm specic transcript (mouse) homolog
14 859359 quinone oxidoreductase homolog
15 42558 glycine amidinotransferase (L-arginine:glycine amidinotransferase)
16 68950 cyclin E1
17 770059 heparan sulfate proteoglycan 2 (perlecan)
18 299737 Homo sapiens clone 24411 mRNA sequence
19 814444 "cofactor required for Sp1 transcriptional activation, subunit 9 (33kD)"
20 25725 farnesyl-diphosphate farnesyltransferase 1
Table 15: Discriminated Class 4 (RMS) from the rest
14
D Comparison of top S2N genes with Khan et al's 96 top
genes
S2N Class rank Khan Rank Khan Class Image Id. Gene Description
1 1 6 1(3) 770394 "Fc fragment of IgG, receptor, transporter, alpha"
1 2 18 1(6) 377461 "caveolin 1, caveolae protein, 22kD"
1 3 75 1(9) 814260 follicular lymphoma variant translocation 1
1 4 73 1(14) 1435862 "antigen identied by monoclonal antibodies 12E7, F21 and O13"
1 5 10 not 1(1) 295985 ESTs
1 6 15 1(2) 866702 "PTP, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase)"
1 7 491565 "Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2"
1 8 1471841 "ATPase, Na+/K+ transporting, alpha 1 polypeptide"
1 9 19 1(7) 52076 olfactomedinrelated ER localized protein
1 10 3 1(11)/3(118) 841641 cyclin D1 (PRAD1: parathyroid adenomatosis 1)
2 1 236282 Wiskott-Aldrich syndrome (ecezema-thrombocytopenia)
2 2 745019 EH domain containing 1
2 3 23 2(8) 183337 "major histocompatibility complex, class II, DM alpha"
2 4 59 not 2(24) 504791 glutathione S-transferase A4
2 5 78 2(105)/4(198) 814526 ESTs
2 6 55 not 2(15) 21652 "catenin (cadherin-associated protein), alpha 1 (102kD)"
2 7 624360 "proteasome(prosome, macropain)subunit, beta type, 8(large multifunctional protease 7)"
2 8 47475 "Homo sapiens inducible protein mRNA, complete cds"
2 9 813742 PTK7 protein tyrosine kinase 7
2 10 66 not 2(20) 897788 "protein tyrosine phosphatase, receptor type, F"
3 1 22 3(2) 812105 transmembrane protein
3 2 786084 chromobox homolog 1 (Drosophila HP1 beta)
3 3 134748 glycine cleavage system protein H (aminomethyl carrier)
3 4 72 3(5) 325182 "cadherin 2, N-cadherin (neuronal)"
3 5 54 3(31) 486110 prolin 2
3 6 11 3(1) 629896 microtubule-associated protein 1B
3 7 810057 cold shock domain protein A
3 8 81518 apelin; peptide ligand for APJ receptor
3 9 756401 Ras homolog enriched in brain 2
3 10 244637 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 45620
4 1 68 4(5) 784224 broblast growth factor receptor 4
4 2 89 4(10) 796258 "sarcoglycan, alpha (50kD dystrophin-associated glycoprotein)"
4 3 7 4(3) 244618 ESTs
4 4 769716 neurobromin 2 (bilateral acoustic neuroma)
4 5 789253 presenilin 2 (Alzheimer disease 4)
4 6 839552 nuclear receptor coactivator 1
4 7 143306 lymphocyte-specic protein 1
4 8 2 4(2) 207274 Human DNA for insulin-like growth factor II (IGF-2); exon 7 and additional ORF
4 9 1 4(1) 296448 insulin-like growth factor 2 (somatomedin A)
4 10 142134 ESTs
Table 16: Top 10 S2N genes discriminating each class and the corresponding Khan et al's overall
rank (top 96) and the category in which they are highly expressed; brackets indicate the rank of
the gene for that category [1].
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E Comparison of top SVMFS genes with Khan et al's 96
top genes
SVMFS Class rank Khan Rank Khan Class Image Id. Gene Description
1 1 139957 ESTs
1 2 754649 chromosome 14 open reading frame 3
1 3 302933 nucleolin
1 4 897690 tumor rejection antigen (gp96) 1
1 5 50887 ESTs
1 6 296448 insulin-like growth factor 2 (somatomedin A)
1 7 15 1(2) 866702 "protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase)"
1 8 7 4(3) 244618 ESTs
1 9 379708
1 10 811000 "lectin, galactoside-binding, soluble, 3 binding protein (galectin 6 binding protein)"
2 1 83 2(71) 868304 "actin, alpha 2, smooth muscle, aorta"
2 2 12 2(12) 840942 "major histocompatibility complex, class II, DP beta 1"
2 3 8 not 2(1) 233721 insulin-like growth factor binding protein 2 (36kD)
2 4 57 1(166)/2(153) 745343 "regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein)"
2 5 47475 "Homo sapiens inducible protein mRNA, complete cds"
2 6 13 2(3) 80109 "major histocompatibility complex, class II, DQ alpha 1"
2 7 1461138 "H4 histone family, member G"
2 8 58 2(27) 241412 E74-like factor 1 (ets domain transcription factor)
2 9 344134 immunoglobulin lambda-like polypeptide 3
2 10 36 not 2(4) 1416782 "creatine kinase, brain"
3 1 11 3(1) 629896 microtubule-associated protein 1B
3 2 22 3(2) 812105 transmembrane protein
3 3 878652 postmeiotic segregation increased 2-like 12
3 4 810057 cold shock domain protein A
3 5 31 3(3) 44563 growth associated protein 43
3 6 30 3(17) 82225 secreted frizzled-related protein 1
3 7 68 4(5) 784224 broblast growth factor receptor 4
3 8 47 3(37) 135688 GATA-binding protein 2
3 9 72 3(5) 325182 "cadherin 2, N-cadherin (neuronal)"
3 10 4 1(25)/4(69) 365826 growth arrest-specic 1
4 1 2 4(2) 207274 Human DNA for insulin-like growth factor II (IGF-2); exon 7 and additional ORF
4 2 68 4(5) 784224 broblast growth factor receptor 4
4 3 1 4(1) 296448 insulin-like growth factor 2 (somatomedin A)
4 4 840708 "superoxide dismutase 2, mitochondrial"
4 5 882522 argininosuccinate synthetase
4 6 302933 nucleolin
4 7 7 4(3) 244618 ESTs
4 8 878798 beta-2-microglobulin
4 9 810512 thrombospondin 1
4 10 19 1(7) 52076 olfactomedinrelated ER localized protein
Table 17: Top 10 SVMFS genes discriminating each class and the corresponding Khan et al's
overall Rank (top 96) and the category in which they are highly expressed; brackets indicate the
rank of the gene for that category [1].
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